mRNA-1403
Phase 2Active 2 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Acute Gastroenteritis
Conditions
Norovirus Acute Gastroenteritis
Trial Timeline
Aug 25, 2023 → Sep 22, 2026
NCT ID
NCT05992935About mRNA-1403
mRNA-1403 is a phase 2 stage product being developed by Moderna for Norovirus Acute Gastroenteritis. The current trial status is active. This product is registered under clinical trial identifier NCT05992935. Target conditions include Norovirus Acute Gastroenteritis.
What happened to similar drugs?
0 of 1 similar drugs in Norovirus Acute Gastroenteritis were approved
Approved (0) Terminated (0) Active (1)
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06592794 | Phase 3 | Active |
| NCT05992935 | Phase 2 | Active |
Competing Products
13 competing products in Norovirus Acute Gastroenteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1403 | Moderna | Phase 3 | 0 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 23 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 22 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 19 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 22 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 19 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 19 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 29 |